Log In
Print
BCIQ
Print
Print this Print this
 

EZN-2279

  Manage Alerts
Collapse Summary General Information
Company Sigma-Tau Group
DescriptionPegylated recombinant adenosine deaminase
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase III
Standard Indication Metabolic (unspecified)
Indication DetailsTreat adenosine deaminase deficiency
Regulatory Designation

Partner

Teijin Pharma Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today